| Assay ID | Title | Year | Journal | Article |
|---|
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
| A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
| High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
| Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
| Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1366185 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure at 1 % w/v after 5 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366190 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure in contralateral eye at 1 % w/v after 2 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366189 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure in contralateral eye at 1 % w/v after 1.5 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366183 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure at 1 % w/v after 3 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366198 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as reduction in intraocular pressure at peak effect time at 1 % w/v by tonometry | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366181 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure at 1 % w/v after 2 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366184 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure at 1 % w/v after 4 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID284022 | Inhibition of MCP1-induced cell migration in U937 cells expressing CCR2 by chemotaxis assay | 2007 | Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
| Design and synthesis of Rho kinase inhibitors (II). |
| AID1366170 | 1-Octanol/water partition coefficient, log P of compound at 2 mg after 24 hrs by spectrophotometry based shake flask method | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366195 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure in contralateral eye at 1 % w/v after 6 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366193 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure in contralateral eye at 1 % w/v after 4 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366192 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure in contralateral eye at 1 % w/v after 3 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366180 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure at 1 % w/v after 1.5 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366188 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure in contralateral eye at 1 % w/v after 1 hr by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID284021 | Inhibition of Rho kinase | 2007 | Bioorganic & medicinal chemistry, Jan-01, Volume: 15, Issue:1
| Design and synthesis of Rho kinase inhibitors (II). |
| AID1366196 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as onset time for reduction in intraocular pressure at 1 % w/v by tonometry | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366191 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure in contralateral eye at 1 % w/v after 2.5 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366179 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure at 1 % w/v after 1 hr by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366186 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure at 1 % w/v after 6 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366197 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as peak effect time for reduction in intraocular pressure at 1 % w/v by tonometry | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366187 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure in contralateral eye at 1 % w/v after 0.5 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366194 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure in contralateral eye at 1 % w/v after 5 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366178 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure at 1 % w/v after 0.5 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| AID1366182 | Reduction in intraocular pressure in Wistar rat model of dexamethasone-induced elevated IOP assessed as change in intraocular pressure at 1 % w/v after 2.5 hrs by tonometry (Rvb = 0%) | 2017 | Bioorganic & medicinal chemistry, 11-01, Volume: 25, Issue:21
| Design and synthesis of benzimidazole-based Rho kinase inhibitors for the treatment of glaucoma. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |